Shares of cell therapy company Talaris Therapeutics (NASDAQ:TALS) are sinking today after it announced the death of a patient in a Phase 3 trial of FCR001 in living donor kidney transplant (LDKT) recipients.
While the data monitoring committee has allowed enrolment and dosing in the trial to continue, the company has kept the U.S. Food and Drug Administration (FDA) abreast of the event.
Talaris shares have nosedived nearly 84.5% over the past year.
Read full Disclosure
